Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M103257200 on May 30, 2001

J. Biol. Chem., Vol. 276, Issue 32, 30490-30498, August 10, 2001
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow An addition or correction has been published
Right arrow All Versions of this Article:
276/32/30490    most recent
M103257200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cunto-Amesty, G.
Right arrow Articles by Kieber-Emmons, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cunto-Amesty, G.
Right arrow Articles by Kieber-Emmons, T.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Directing the Immune Response to Carbohydrate Antigens*

Gina Cunto-AmestyDagger , Tarun K. Dam§, Ping LuoDagger , Behjatolah Monzavi-KarbassiDagger , C. Fred Brewer§, Thomas C. Van Cott, and Thomas Kieber-EmmonsDagger ||

From the Dagger  Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, the § Department of Molecular Pharmacology and Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York 10461, and the  Henry M. Jackson Foundation, Rockville, Maryland 20850

Received for publication, April 11, 2001, and in revised form, May 30, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Peptide mimetics may substitute for carbohydrate antigens in vaccine design applications. At present, the structural and immunological aspects of antigenic mimicry, which translate into immunologic mimicry, as well as the functional correlates of each, are unknown. In contrast to screening peptide display libraries, we demonstrate the feasibility of a structure-assisted vaccine design approach to identify functional mimeotopes. By using concanavalin A (ConA), as a recognition template, peptide mimetics reactive with ConA were identified. Designed peptides were observed to compete with synthetic carbohydrate probes for ConA binding, as demonstrated by enzyme-linked immunosorbent assay and isothermal titration calorimetry (ITC) analysis. ITC measurements indicate that a multivalent form of one particular mimetic binds to ConA with similar affinity as does trimannoside. Splenocytes from mimeotope-immunized mice display a peptide-specific cellular response, confirming a T-cell-dependent nature for the mimetic. As ConA binds to the Envelope protein of the human immunodeficiency virus, type 1 (HIV-1), we observed that mimeotope-induced serum also binds to HIV-1-infected cells, as assessed by flow cytometry, and could neutralize T-cell line adapted HIV-1 isolates in vitro, albeit at low titers. These studies emphasize that mimicry is based more upon functional rather than structural determinants that regulate mimeotope-induced T-dependent antibody responses to polysaccharide and emphasize that rational approaches can be employed to develop further vaccine candidates.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Targeting carbohydrate antigens is a major challenge in vaccine design. Carbohydrates fail to elicit memory responses, as they are T-cell-independent antigens (1-3). Conversion of a polysaccharide (PS)1 antigen to a thymus-dependent antigen, by covalent coupling to an immunogenic protein carrier, alters the response to PS in several important ways (4-6). However, conjugation strategies that elicit carrier-specific T- and B-cell responses do not necessarily enhance PS immunogenicity (7) nor do PS conjugates elicit responses in immunodeficient mice. Furthermore, in cases where a large number of carbohydrate antigens are required to afford protection, much like that representative of the large number of pneumococcal carbohydrate serotypes, PS conjugates will be far more complicated to produce (6).

Immunization with peptide mimetics of carbohydrate antigens can overcome the T-cell-independent nature of the immune response (8-12). Peptide antigens have an absolute requirement for T cells that can mediate memory responses upon carbohydrate boosting (11, 13). In contrast to carbohydrate conjugates, peptide mimetic conjugates can facilitate cognate interactions between B and T cells after immunization of immunodeficient mice that lack Bruton's tyrosine kinase (10). Peptide mimetics therefore afford a vaccine approach to break tolerance to carbohydrate self-antigens (13).

Whereas peptide library screening has led to the identification of a variety of peptide mimetics of carbohydrate antigens (14, 15), concepts described for the design of small molecules may apply equally well to the design of mimetics of carbohydrate antigens (16, 17). To further facilitate concepts for a structure-assisted vaccine design, we considered, as a model system, small molecule interactions with concanavalin A (ConA). The mannose/glucose-specific lectin ConA is the most extensively studied plant lectin, known for its application as a biochemical tool and as a model protein to gain further knowledge about lectin-ligand interactions (18-20). Lectins are also particularly relevant to human immunodeficiency virus (HIV) pathogenesis. Lectin-induced inhibition of syncytium formation and infection of cells by both T-cell line adapted and primary isolates (21-27) focuses attention on oligomannosidic glycans, such as those characterized by interaction with ConA (Fig. 1). More recently the lectin DC-SIGN, expressed on dendritic cells, has been recognized to participate in facilitating HIV transmission (24, 28, 29). Consequently, defining peptide mimetics reactive with ConA may facilitate the development of immunogens to augment carbohydrate responses to HIV in future vaccine applications.


View larger version (19K):
[in this window]
[in a new window]
  		Fig. 1.   Representative carbohydrate antigen structures expressed on gp120, as defined by specific molecular reagents (antibodies and lectins). Monoclonal antibodies reactive with sialyl-Tn, LeY, and A1 neutralize HIV infection in vitro (65). Lectins reactive with mannose-containing carbohydrates also the display ability to block infection.

Structural studies of peptidyl-ConA complexes suggest that the carbohydrate-binding site on ConA can accommodate an extended array of carbohydrate antigens that might lend to its biological properties (30, 31). We have further defined a peptide that binds at or near the carbohydrate-binding site of ConA that displays a free energy of association comparable to those reported for core trimannoside-ConA and pentasaccharide-ConA interactions. The designed peptide elicits a robust thymus-dependent response, stimulating splenocytes from peptide-immunized mice. We observe that the peptide, rendered as a multiple antigenic peptide (MAP), used to emulate the clustered array of Envelope protein of HIV (Env)-associated carbohydrates (32) induced an antibody response reactive with cell-bound Env protein. We observe that serum induced to the peptide mimetic paralleled neutralization results obtained by using a mannan preparation from Saccharomyces cerevisiae or from Candida albicans (33, 34), which further suggests that carbohydrate cross-reactive responses induced by peptide mimetics might be rendered even more effective immunogens.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Epitope Mapping of ConA Ligand-binding Site-- By using the crystallographically positioned pentasaccharide structure within the ConA-combining site, we implemented the program Ligand-Design (LUDI (35), Micron Separations/Biosym Technologies), as described previously (36-39), to search a fragment library and identify amino acid residue types able to interact with ConA. This program identifies small molecular fragments in a data base and then docks them into the protein-binding site in such a way that hydrogen bonds and ionic interactions can be formed between the protein and the molecular fragments. The positioning of the small fragments is based upon rules about energetically favorable non-bonded contacts and on geometry between functional groups of the protein and the ligand. The center of search was defined using the crystallographic position of the central mannose residue and searching 15 Å surrounding the centroid of the sugar for potential contact sites on ConA.

The search was performed using standard default values and a fragment library supplied with the program. Peptides were built using INSIGHTII (Micron Separations/Biosym Technologies) and accommodated in relation to the docked LUDI fragments. The peptide backbone and side chain torsion angles were rotated using a fixed docking algorithm (affinity program) within INSIGHTII, until the side chains of the peptide were approximated to the corresponding LUDI fragments. The peptide-ConA complex was subjected to energy optimization and molecular dynamic simulations, as described previously(36-39).

Reagents and Immunizations-- Multivalent carbohydrates Lewis Y (LeY), alpha -D-mannose (Man-9), disialyl-biantennary (A2), asialo-biantennary (NA-2), and oligomannose 9 (Man-9), each attached to a polyacrylamide polymer of ~30 kDa, were purchased from GlycoTech Corp., Rockville, MD. Methyl-alpha -D-mannopyranoside (Mealpha Man) was purchased from Sigma. Peptides were synthesized as MAP (Research Genetics, Huntsville, AL) by Fmoc (N-(9-fluorenyl)methoxycarbonyl) synthesis on polylysine groups, resulting in the presentation of eight peptide clusters. Linear peptides were synthesized by standard solid phase (Research Genetic, Huntsville, AL) and were high pressure liquid chromatography-purified. The structures were confirmed by fast atom bombardment-mass spectrometry.

ConA was either prepared from jack bean (Canavalia ensiformis) seeds (Sigma), as described previously (20), or obtained from Sigma. The concentration of ConA was determined spectrophotometrically, at 280 nm, using A1%,1 cm = 13.7 (pH 7.2) and 12.4 (pH 5.2) and expressed in terms of monomer (Mr = 25,600).

BALB/c mice (n = 4 per group), 4-6 weeks of age, were immunized intraperitoneally three times, at intervals of 2 weeks, with 100 µg of a respective peptide or 50 µg of LeY, each combined with 20 µg of the adjuvant QS21 (Aquila Biopharmaceuticals Inc., Framingham, MA). A control group was immunized with QS21 alone. The LeY-expressing cell line MCF7 (ATCC, Manassas, VA) (40), without adjuvant, was also used to immunize groups of mice four times. Serum was collected at days 7 and 14 after the last immunization and stored at -80 °C until use.

ELISA-- ELISAs were performed as described (41). Immulon-2 plates were coated overnight, at 4 °C, with 100 mM of a selected peptide or carbohydrate probe to assess the binding of sera to these antigens. After blocking the plates (PBS, 0.5% FCS, and 0.2% Tween 20), serial dilutions of sera were added and resolved with anti-mouse isotype-matched HRP (Sigma). To assess the binding of ConA to carbohydrates and peptides, serial concentrations (10 to 0.6 ng/ml) of ConA biotin-labeled (Sigma) were added to pre-coated plates and reacted with streptavidin-HRP (Sigma). All results were calculated from triplicate measurements.

Peptide-Carbohydrate Competition Assay-- Immulon-2 plates pre-coated with 20 µg/ml peptide were blocked. The binding of ConA (0.4 µg/ml) biotin-labeled (Sigma) to peptides was assessed in the presence of serial concentrations of Mealpha Man (0.8-50 mM). Control wells with ConA, but not Mealpha Man, were also run. Plates were reacted with streptavidin-HRP (Sigma) and results calculated from triplicate measurements. Percentage of inhibition of ConA binding to peptides was calculates as 1 - (mean of test well/mean of control wells) × 100.

Isothermal Titration Calorimetry-- Isothermal titration calorimetry (ITC) was performed using an MCS isothermal titration calorimeter (Microcal Software, Northampton, MA). In individual titrations, injections of 5 µl of peptides (0.4-5.2 mM) and concentration of ConA ranging from 0.025 to 0.2 mM were added from the computer-controlled microsyringe, at an interval of 4 min, into the lectin solution (cell volume = 1.3582 ml), while stirring at 350 rpm, at 27 °C. Both lectin and peptide were dissolved in 100 mM HEPES buffer (pH 7.2) or 100 mM sodium acetate buffer (pH 5.2), containing 5 mM CaCl2 and MnCl2. Control experiments were performed by making identical injections of peptide into a cell-containing buffer, where protein showed insignificant heats of dilution. The experimental data were fitted to a theoretical titration curve using software supplied by Microcal Software. The quantity c = Ka Mt(0), where Mt(0) is the initial macromolecule concentration, is of importance in titration calorimetry. All experiments were performed with c values 1 < c < 200. The instrument was calibrated using the calibration kit containing RNase A and 2'-CMP, supplied by the manufacturer. Thermodynamic parameters were calculated from the equation, Delta G = -RT ln Ka, where Ka and Delta G are the association constant and changes in free energy, respectively; T is the absolute temperature, and R = 1.98 cal mol-1 K-1 .

Precipitation Study-- Measured volumes of known concentrations of lectin and peptide solutions (in 100 mM HEPES buffer (pH 7.2) containing 150 mM NaCl, 5 mM CaCl2, and MnCl2) were mixed in a quartz cuvette, at room temperature, and the time-dependent development of turbidity was measured at 420 nm (42). Absorbances were monitored continuously, until they remained constant. A portion of the precipitate was treated with 400 mM Mealpha Man, to check whether or not the precipitation was due to the binding of the peptide at the carbohydrate-binding sites of the lectin. Absorbancy of the solution was recorded at 420 nm, before and after the addition of Mealpha Man.

Cell Proliferation Assay-- Spleens were aseptically removed and splenocytes, as the responder cells, isolated by lysis of erythrocytes. Responder cells were used for detection of cell proliferation using CellTiter 96R Aqueous One Solution (Promega, Madison, WI), based on the manufacturer's instructions. Briefly, cells (2.5 × 105/well) were cultured in a flat-bottomed 96-well plate with 106-MAP, 911-MAP, or only medium RPMI 1640 (Life Technologies, Inc.) supplemented with 5% heat-inactivated fetal calf serum (FCS), 1% L-glutamine, 100 IU/ml penicillin, and 100 µg/ml streptomycin. At the 3rd day of incubation, the provided solution was added to each well, and plates were incubated for an additional 1-2 h in a humidified 5% CO2 incubator at 37 °C. As an indicator of cell proliferation, absorbancy was measured at 490 nm, using a 96-well plate reader (Spectra Fluor, Tecan, Research Triangle Park, NC),

Cells and Antibodies for Fluorescence-activated Cell Sorter-- Sup-T1, a non-Hodgkin's T-cell lymphoma cell line (43), and the same cells stably infected with HIV type 1, III-B (A1953), were kindly provided by Dr. J. Hoxie. The mouse monoclonal antibody 902, specific for gp120 of HIV-1 III-B (44, 45), was used to differentiate infected versus non-infected cells. Mouse sera were tested with dilutions ranging between 1:10 and 1:100. The secondary antibody used was anti-mouse IgG (gamma -specific), fluorescein-conjugated isothiocyanate (Sigma). Cells were fixed for 30 min with 4% paraformaldehyde diluted in PBS. Acquisition of data was performed by using the FACSCAN flow cytometer and histogram analysis by using the CELLQuest software (Becton Dickinson Immunocytometry Systems, Mansfield, MA).

Propagation of HIV-1 Isolates-- CEM × 174 cells (1 × 105/ml), in RPMI 1640 media with 20% FCS, 100 IU/ml penicillin, 100 µg/ml streptomycin, 1% L-glutamine, and 1% HEPES (R-20), were used to propagate the HIV-1 strains III-B (46-48) and MN (49-51). When most cells evidenced a virus-induced cytopathic effect (CPE), virus-containing supernatants were collected after centrifugation (200 × g for 10 min) and filtration (0.45 nm filters), to be stored at -80 °C, until use.

Determination of the TCID50-- The procedure was performed as reported (52). Briefly, 200 µl/well of a viral isolate, diluted 1:3 in R-20, were added in sextuplicates in flat-bottomed 96-well plates. 50 µl from these wells were admixed with 150 µl of R-20 in wells of the next row, and so, in successive rows (total of 20 serial dilutions). 2 × 104 MT2 cells (53, 54) per well, in 50 µl of R-20, were added and incubated at 37 °C in a humidified atmosphere with 5% CO2. Cells were fed as necessary, all wells at the same time, and observed daily for presence of CPE. When no further migration of CPE was evident, wells were scored either positive (presence of CPE) or negative (absence of CPE), and TCID50 values were calculated by using the method of Reed and Muench (52).

Neutralization Assays-- Test sera were obtained from immunized mice and control sera from pre-immune mice (normal mouse serum) and from normal and HIV-infected human individuals (IHS, respectively). Sera were inactivated at 56 °C for 1 h and sterilized by exposure to UV light. Determined dilutions of sera and viral outputs were admixed and incubated for 1 h at 37 °C and then added (25 µl) in triplicated or sextuplicated wells (round-bottomed 96-well plates) containing 104 CEMx174 cells resuspended in 175 µl of R-20. Plates were incubated for 24-40 h. Control wells without virus or serum (uninfected wells) or without serum but with a selected viral isolate (infected wells) were assayed. After incubation, cells were washed, resuspended in 200 µl of R-20, and transferred to homologous flat-bottomed 96-well plates. Media were replaced at the same time in all plates, as necessary. Cultures were maintained until no further progression of CPE was observed in infected control wells, and at this time 25 µl of supernatant per well were admixed with 225 µl of 0.5% Triton X-100 (lysing solution) for p24 antigen detection by ELISA. Samples were stored at -80 °C, until use. Percentage of neutralization was calculated as 1 - (mean absorbancy of test wells/mean absorbancy of infected control well) × 100.

ELISAs to Determine HIV-1 p24-- The assay was performed by using the HIV-1 p24 Antigen Capture Assay Kit from the AIDS Vaccine Program of the NCI-Frederick Cancer Research and Development Center (Frederick, MD). Briefly, plates pre-coated with a monoclonal anti-HIV-1 p24 antigen were washed and blocked with PBS, 0.5% FCS and 0.2% Tween 20. Supernatant lysates were added in duplicates and incubated at 37 °C for 2 h. A rabbit anti-HIV-1 p24 serum and a goat anti-rabbit IgG (H & L)-HRP-labeled antibody were used in successive steps. 3,3',5,5'-Tetramethylbenzidine-peroxidase substrate (0.1 mg/ml) (Sigma), in 0.05 M phosphate-citrate buffer and 0.03% sodium perborate buffer (Sigma), was allowed to react for 20 min. Reaction was stopped with 4 N H2SO4, and plates were read as described (41).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Peptidyl Ligands That Bind to ConA-- Crystallographic analysis of ConA complexed with the trimannoside alpha -D-Man-(1-6)-alpha -D-Man-(1-3)-D-Man (55) and the pentasaccharide beta -GlcNAc-(1-2)-alpha -Man-(1-3)-[beta -GlcNAc- (1-2)-alpha -Man-(1-6)]-Man (56) provides a template to compare peptide-ConA complexes. Prototypic peptides that have been defined to bind ConA include 908 and 712 (Table I) (30). CD analyses of these binding analogs indicate that they share a similar CD profile (30). Secondary structure comparison of these two peptide sequences indicates similarities in tertiary class type, except in the all-beta prediction, in which an extended structure spans the WYPY sequence tract of MYWYPYASGS (Table I) (57). Although the YPY motif can be viewed as adopting a beta -turn conformation that might emulate the spatial position of the trimannoside configuration (31), an extended conformation might also be plausible for mimetics to interact with ConA. An extended structure conformation is observed in Sesbania mosaic virus coat protein (deposited in the Protein Data Bank at Rutgers University, New Brunswick, NJ) (58) for the homologue sequence WYPY. The extended structure can overlap with the pentasaccharide within the ConA-binding site (Fig. 2A).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Peptides used in this study and their secondary structure properties
The secondary structure profiles were calculated from neural network calculations.


View larger version (25K):
[in this window]
[in a new window]
  		Fig. 2.   A, overlap of the extended structure of prototypic WYPY with the pentasaccharide (beta -GlcNAc-(1-2)-alpha -Man-(1-3)-[beta -GlcNAc-(1-2)-alpha -Man-(1-6)]-Man). The Trp overlaps with the first GlcNAc-(1-2) on the Man-(1-3) side, with the proline residue overlapping with central alpha -Man-(1-6) moiety. The Tyr at the 4th position in the sequence tract approximates the location of the second GlcNAc residue. Holding the Pro residue, fixed relative to the centralized mannose ring, least squares fitting of the backbone atoms, comprising the first three residues in the WYPY motif to the alpha 1-6 linkage in the alpha -D-Man-(1-6)-D-Man-(1-3) alpha -D-Man binding mode, resulted in a root mean square deviation of 0.18 A. B, representative placement of LUDI identified guanidinium-like moieties. C, putative 912 peptide (yellow) sitting in ConA carbohydrate-binding site, emphasizing the extended nature of the putative interacting motif.

We attempted to identify amino acid sequences that could adopt the extended secondary profile and display an adequate interaction with the ConA site. To identify likely residue types that can interact with ConA, we used the program LUDI. We have shown previously that LUDI could be used to structurally map the binding of peptide mimetics to the combining site of anti-carbohydrate antibodies (36, 39). By using this approach, LUDI identified 153 interacting ligands for ConA, with some contacting the same sites as the pentasaccharide. In the search procedure, we identified moieties with Tyr- and Trp-like side changes and guanidinium groups that fit within the ConA site, but not always in the same fashion as the pentasaccharide (Fig. 2B). Substitution of Arg for Pro within the prototypic peptide 908 conserves the extended structure (peptide 909 in Table I), as does a concomitant substitution of the first Tyr in the 909 peptide with a Trp residue forming the 910 sequence (Table I).

To test the ability of the peptide analogs to bind to ConA, MAP forms of the peptides 908, 909, and 910 were synthesized. The MAP forms all bound to ConA in a concentration-dependent manner, with parallel activity (data not shown). Competition analysis with solid phase 908-MAP indicated that Mealpha Man inhibits ConA peptide reactivity in a concentration-dependent manner, reaching a plateau of about 60% inhibition at a 1.6 mM concentration of Mealpha Man, a 100-fold less concentration effect than reported previously (30) (Fig. 3). As expected, lactose, as control inhibitor, did not affect ConA peptide binding (data not shown). The variant MAPs 909 and 910 displayed some differences in the Mealpha Man inhibition profile compared with 908-MAP. At a 1.6 mM concentration, Mealpha Man inhibited about 20 and 45% of ConA binding to 910-MAP and 909-MAP, respectively.


View larger version (11K):
[in this window]
[in a new window]
  		Fig. 3.   Inhibition of ConA binding to solid phase MAP by soluble Mealpha Man in competitive lectin-binding assay. Biotinylated ConA (0.4 µg/ml) was incubated with an increasing amount of Mealpha Man, and binding of free biotinylated lectin to MAPs was measured using peroxidase-labeled streptavidin. Lactose did not display any inhibition of ConA binding to the peptides.

We further defined a putative peptide sequence, RYGRY, in which the Pro residue in the WYPY motif was replaced by Gly, with the first and fourth Tyr replaced by Arg, and the addition of a Tyr at the fifth position. This putative sequence was chosen because of the identification of these residues and their ConA-reactive positions by LUDI analysis. The peptide motif represented in Fig. 2C, involving the putative RYGRY tract of peptide 912 (Table I), maintains an extended secondary structure profile spanning these residues (Table I). Relative to the other class types, this peptide sequence is the same as that for peptides 908 and 712 and is perhaps more like 712, as represented in the all-beta class (Table I). The putative RYGRY tract makes contact with 3 residues within ConA, as does the central mannose residue. A bifurcated hydrogen bond between the guanidinium group of Arg, at the 4th position, and Ser-21 and Tyr-12 side chains of ConA, and a bifurcated hydrogen bond between the guanidinium group of Arg, at the 1st position, and Ser-223 and Ser-168, are observed (Table II). The root mean square deviation of the ConA-peptide complex, after minimization and dynamics calculations, was found to be 1.2 Å, compared with the ConA-pentasaccharide complex, indicating that the extended structure is readily accommodated within the ConA site.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Hydrogen bonding scheme of putative carbohydrate and peptide constituents with ConA
Hydrogen bonding schemes are from crystal structure contacts in the pentasaccharide complex structure. The mannose core designation is for the trimannoside alpha -D-Man (1-6)-alpha -D-Man (1-3)-D-Man constituents of the pentasaccharide. The Tri-sac designation is for beta -D-GlcNAc-(1-2)alpha -D-Man (1-6)-D-Man constituents of the full pentasaccharide. The central mannopyroside makes the most contacts with ConA. Amino acid designation in the peptide model is positional location in the RYGRY sequence. In addition to hydrogen bonds, Tyr-2 forms a stacking interaction with Tyr-100 of ConA. The Interaction Energies (IE) were calculated for the respective structures within the ConA site. BB, Backbone; SC, side chain.

Experimentally, ConA displays higher affinity for alpha -D-Man-(1-6)alpha -D-Man-(1-3) D-Man constituents over beta -D-GlcNAc (1-2)alpha -D-Man-(1-6) D-Man, paralleling the intermolecular interaction (interaction energy) calculation trends shown in Table II. The calculated location for the peptide mimetic is, however, not an optimal binding mode in terms of mimicking the conformational properties of the pentasaccharide and in contacting the same ConA residues, as does the pentasaccharide (Table II). Nevertheless, the interaction energy for this ConA/peptide-binding mode was found to be -75.9 kcal/mol, falling within the range of interaction energies calculated for the trimannoside constituent (Table II).

Peptide Mimetic Competes for Carbohydrate Binding to ConA-- Clustering or repeating the 912 sequence, forming the peptide 911, manifests an extended secondary structure (Table I). ELISAs carried out using various concentrations of ConA showed a concentration-dependent binding to the clustered form of the RYGRY containing peptide 911, which was inhibited by Mealpha Man (Fig. 4A). We observed binding of ConA to 911-MAP, at ConA concentrations lower than those required for binding to ligands tested, which included extended structure peptides, and better than that for binding to 908-MAP. This result suggests a high avidity interaction of ConA with the multivalent 911 peptide and therefore requires a higher concentration of Mealpha Man for inhibition of 911-MAP binding to ConA than that for the 908-MAP (Fig. 4B).


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 4.   A, serial dilutions of ConA biotin-labeled were added to ELISA plates pre-coated with selected carbohydrate probes or peptide mimeotopes (100 nM/well) and reacted with streptavidin-HRP. Absorbancy readings at 450 nm demonstrate that ConA binds to 911 peptide more efficiently than to other peptides or to carbohydrate probes known to be reactive with ConA. B, inhibition of ConA binding to solid phase 911-MAP by soluble Mealpha Man in competitive lectin-binding assay. Biotinylated ConA (0.4 µg/ml) was incubated with an increasing amount of Mealpha Man, and binding of free biotinylated lectin to 911-MAP was measured using peroxidase-labeled streptavidin. Lactose did not display any inhibition of ConA binding to the 911-MAP.

The putative monovalent peptide 912 and 911-MAP binding to ConA was studied further by ITC, to determine the binding parameters such as Ka and Delta G. Experimental conditions were previously standardized for studies of multivalent interaction by ITC (9). The association constant (Ka) (1.1 × 104 M-1) and Delta G (5.6 kcal mol-1) values of ConA for the monovalent 912 peptide were observed to be comparable to that observed for Mealpha Man (Fig. 5). Earlier, microcalorimetric studies showed that the Ka and Delta G values of ConA for carbohydrate ligands, such as Mealpha Man, trimannoside, and pentasaccharide, were 0.82 × 104, 49 × 104, and 92 × 104 M-1 and 5.3, 7.8, and 8.1 kcal mol-1, respectively (20). In contrast, Ka of ConA for 911-MAP was found to be 26 × 104 M-1, with a value for Delta G of 7.4 kcal mol-1. These results indicate that the multivalent 911 peptide displays a comparable association constant and free energy of binding, as do oligosaccharide ligands.


View larger version (25K):
[in this window]
[in a new window]
  		Fig. 5.   ITC profile of ConA (0.2 mM) with 912 peptide (5.2 mM), at 27 °C. Top, data obtained from 20 automatic injections, 6 µl each, of 912 peptide. Bottom, the integrated curve showing points (squares) and best fit (line). The buffer was 0.1 M HEPES with 5 mM each of CaCl2 and MnCl2.

To verify further the valence of the peptides for ConA, a precipitation study was carried out (Fig. 6). The number of binding site per monomer (n), as determined by ITC, suggests that peptide 912 is monovalent, whereas 911-MAP is multivalent for ConA. Multivalent lectin-ligand interactions often lead to the formation of insoluble cross-linked complexes, which can easily be monitored spectrophotometrically by measuring the absorbancy at 420 nm. The efficient precipitation by the 911-MAP form confirms that it possesses multiple binding sites for ConA. About 70% of the cross-linked complexes are re-dissolved when treated with Mealpha Man (400 mM). This observation clearly indicated that 911-MAP was bound to ConA predominantly through the carbohydrate-binding sites of the lectin, whereas the remaining ~30% of precipitation is probably due to protein-protein interactions. Peptide 912 was unable to form any detectable precipitate, which confirms its monovalent nature (Fig. 6).


View larger version (26K):
[in this window]
[in a new window]
  		Fig. 6.   Profile for the kinetics of precipitation of ConA (60 µM) in the presence of 911-MAP (15 µM) and peptide 912 (squares, 911-MAP; circles, 912).

Binding of Serum from Immunized Mice to HIV-1 III-B-infected Cells-- The 911 peptide is predicted to have a major histocompatibility complex class II motif spanning the RYRYGRYRS sequence. Immunization with peptide 911 indicated a robust cellular response specific for peptide 911 (Fig. 7). To determine if serum antibodies react with membrane-expressed gp120/gp41, we examined serum IgG binding to constitutively infected cells compared with the binding to the same non-infected cells. Results in Fig. 8 show IgG antibody binding to chronically infected cells (A1953 cells). We observe that the monoclonal antibody 902 differentiates infected from non-infected cells (Fig. 8A). Immunization with control MCF7 cells induce serum reactive with the neolactoseries antigen LeY (13) and also antibodies that are potentially reactive with major histocompatibility complex class I, which shares some homology with gp120, as anti-class I antibodies bind to Env protein (Fig. 8B) (59, 60). Serum from 911-immunized mice reacted stronger with infected cells than non-infected cells (Fig. 8C). IgG from mice immunized with other formulations (LeY or QS21) did not show any significant increased binding to A1953 cells compared with their binding to Sup-T1 cells (data not shown).


View larger version (10K):
[in this window]
[in a new window]
  		Fig. 7.   911 peptide-stimulated proliferation of splenocytes from 911 peptide-immunized mice. Mice were immunized with MAP form of 911 peptide two times at 3-week intervals. 7 days after the boost, splenocytes were collected and used for detection of cell proliferative response to MAPs 106 and 911, using CellTiter 96R Aqueous One Solution (Promega, Madison, WI). MAPs were used at 5 and 1 µg/ml final concentrations. Results are given as mean ± S.D. based on three replications. Experiment was repeated three times with comparable results using pooled splenocytes from four mice. Peptide 106 (GGIYWRYDIYWRYDIYWRYD) is also in the MAP format and displays a major histocompatibility complex binding score of 2000.


View larger version (31K):
[in this window]
[in a new window]
  		Fig. 8.   Binding of serum IgG from mice immunized with 911 and MCF7 to Sup-T1 cells (column 1) or to A1953 (Sup-T1 cells infected with HIV-1 III-B) (column 2). Dotted lines represent the binding of IgG from pre-immune mouse serum. A shows the binding of the monoclonal antibody 902 (mouse IgG1-k, specific for gp120 of HIV-1 III-B) to the respective cells; B shows the binding of MCF7-IgG; and C shows the binding of 911-IgG. Serum dilution used in these assays was 1:100.

Immune Serum Affects in Vitro Neutralization-- The neutralizing activity of the serum was assessed by p24 ELISA. In Fig. 9A, we observe that serum from MCF7- and 911-MAP-immunized mice were able to neutralize a viral input of 100 TCID50 of HIV-1 III-B, up to 1:128 dilutions, with a calculated percentage of neutralization of about 80% for each, reflecting a reduction of p24 antigen in supernatants. In contrast, serum to 910 peptide did not neutralize this viral load at 1:64 dilutions. Positive control (IHS) displayed a neutralizing capability beyond 1:512 dilution.


View larger version (24K):
[in this window]
[in a new window]
  		Fig. 9.   The activity of sera from mice immunized with different formulations of immunogens to neutralize HIV-1 III-B was assessed by p24 ELISA. Percentage of neutralization was calculated. A, the data using a viral input of 100 TCID50. B, the data with a viral input of 200 TCID50.

By increasing the viral load to 200 TCID50 (Fig. 9B), IHS still displayed neutralizing activity, whereas MCF7 serum retained some neutralizing capacity, better than that for serum raised to 911-MAP. However, in a representative neutralization assay of 50 TCID50 of HIV-1 III-B, the 911-MAP serum displayed neutralization capability with dilutions up to 1:256 (data not shown). As with III-B, 911-MAP serum was able to neutralize 100 TCID50 of MN, at 1:128 dilutions, with partial neutralization activity at 1:256 dilution (data not shown). Negative controls, normal human serum and normal mouse serum, did not show neutralizing capabilities to any viral isolate, even at low dilutions.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Carbohydrate antigens are important targets in vaccine development. Vaccine design strategies have little utilized structural concepts to develop novel carbohydrate forms (61). The clustering and multivalent presentation of carbohydrate antigens appears relevant to induce antibody responses to natively expressed carbohydrate antigens on cell surfaces (13, 62, 63). We have shown that peptide mimeotopes can elicit carbohydrate cross-reactive immune responses to natively expressed bacterial and tumoral antigens related to those expressed on HIV-1 Env glycoprotein (9, 13, 41). To explore further the utility of targeting the Env glycoprotein and generalizing peptide design strategies (39, 64), we are optimizing peptides reactive with ConA seen as a template. The mimetics described here represent rationally designed candidate immunogens despite significant gaps in our knowledge regarding the molecular and functional characteristics of PS mimeotopes (12).

We identified a peptide that, rendered as a clustered and multivalent form, was reactive with ConA at lower concentrations than those required for reaction of some native oligosaccharide ligands of ConA. The 911-MAP displayed competitive inhibition with carbohydrate ligands of ConA, indicating that it binds at an overlapping carbohydrate-binding site on ConA. ITC and precipitation experiments suggest that the putative peptide 912 is monovalent for ConA, and its affinity is comparatively weak (similar to that of Mealpha Man). The MAP format of peptide 911 resulted in a higher association constant and free energy of association with ConA compared with that found upon binding of the putative 912 peptide. Detailed thermodynamic analysis of binding of trimannoside to ConA has been performed by ITC (18, 20), and the Ka and Delta G values of 911-MAP are comparable to those of ConA-reactive trimannoside and pentasaccharide.

Whereas the enhancement in Ka of 911-MAP (relative to 912) is due to multivalent presentation, the increased affinity of the two carbohydrate ligands (compared with the monosaccharide) is an outcome of an extended site interaction. Initial analysis of binding raw data obtained from ConA-911-MAP titration, and its comparison with the data of multivalent sugars, points to certain fundamental differences in the overall binding mechanism. Differences between two multivalent binding systems are primarily attributed to the structural dissimilarities of the peptide and carbohydrate ligands, a conclusion indicated from the molecular modeling study. It has previously been observed that even a minor structural alteration in lectin structure profoundly affects the binding thermodynamics. ConA and the homologous lectin from Dioclea grandiflora possess conserved binding sites for the pentasaccharide, yet minor differences in the lectin structure result in a totally different binding energetic for the oligosaccharide. D. grandiflora binds the pentasaccharide with much lower Ka values than does ConA (20). Therefore, it is possible that structural differences between the peptide and carbohydrate ligands contribute to the lower Ka value of the 912 peptide (compared with the pentasaccharide). However, the affinity is significantly boosted in the MAP format, where the peptide is functionally multivalent.

Many naturally occurring carbohydrates, including glycoproteins, are multivalent, which results in increased avidity for lectins and antibodies. This characteristic must be emulated to affect functional immune responses (13). Although the benefits of multivalency are well established for both antibody and lectin binding to carbohydrates, the molecular mechanisms underlying these phenomena are poorly understood. Presumably, the effect is not attributable to the recognition of a combined epitope encompassing three or more sugar chains, as such a structure would exceed the size of an antibody-combining site (39). It is probable that multivalency contributes both to structural properties and entropy involved in binding (19). It is likely that the density of antigen expressed on cell or pathogen surfaces can play a significant role in mediating avidity interactions.

We have shown that the 911 peptide mimetic, formulated as a MAP form, can induce functional carbohydrate cross-reactive antibodies, in concordance with our other studies (13, 41). 911-MAP induces serum that neutralizes HIV-1 III-B at levels comparable to serum induced by MCF7 cells, using a viral input of 100 TCID50. For lower viral inputs (50TCID50), anti-911 serum neutralizes the same isolate up to 90% at 1:256 dilution (data not shown). The presentation of the MAP form of the mimeotopes, while emulating the multivalent carbohydrate surface, may still not effectively cope with micro-heterogeneity in carbohydrate structures. However, this same problem exists when immunizing with carbohydrate immunogens, since, many times, synthetic carbohydrate forms do not induce responses cross-reactive with native carbohydrate forms, requiring modifications in synthetic strategies. Likewise, cyclization of peptide mimetic immunogens may further restrict carbohydrate cross-reactive responses much as it does in inducing responses to protein antigens, by limiting the polyclonal response.

In summary, these results indicate that designed peptide mimetics of carbohydrate antigens can induce functional responses that may find utility in priming strategies to further augment carbohydrate immune responses against pathogens or tumor cells (11). Although modeling does not account for multivalent interactions, as represented by MAP forms, modeling can define potential binding site constituents. Consequently, strategies that evaluate potential mimetic binding modes and thermodynamics of binding should further facilitate structure-assisted design of surrogates for vaccine applications. Likewise, this study encourages further investigation to ascertain the mechanism(s) by which certain peptide mimics of PS antigens play their role as mimeotopes, in that they can stimulate immunity that targets PS (12).

    ACKNOWLEDGEMENTS

We thank Kaity Lin for technical assistance. We thank Dr. James Hoxie of the University of Pennsylvania for the A1953 (Sup-T1 cells stably infected with HIV-1 III-B) cells. We thank Charlotte Read Kensil of Aquila Biopharmaceuticals Inc. for the QS21.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant AI44412.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence should be addressed: Dept. of Pathology and Laboratory Medicine, Rm. 205, John Morgan Bldg., 36th and Hamilton Walk, Philadelphia, PA 19104-6082. Tel.: 215-898-2428; Fax: 215-898-2401.

Published, JBC Papers in Press, May 30, 2001, DOI 10.1074/jbc.M103257200

    ABBREVIATIONS

The abbreviations used are: PS, polysaccharide; ELISA, enzyme-linked immunosorbent assay; ITC, isothermal titration calorimetry; ConA, concanavalin A; HIV-1, human immunodeficiency virus, type 1; MAP, multiple antigenic peptide; Env, envelope; LeY, Lewis Y; PBS, phosphate-buffered saline; FCS, fetal calf serum; HRP, horseradish peroxidase; Mealpha Man, methyl-alpha -D-mannopyranoside; CPE, cytopathic effect; IHS, HIV-infected human individuals.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Stein, K. E. (1992) J. Infect. Dis. 165 Suppl. 1, 549-552
2. Mond, J. J., Lees, A., and Snapper, C. M. (1995) Annu. Rev. Immunol. 13, 655-692
3. Vos, Q., Lees, A., Wu, Z. Q., Snapper, C. M., and Mond, J. J. (2000) Immunol. Rev. 176, 154-170
4. Robbins, J. B., and Schneerson, R. (1990) J. Infect. Dis. 161, 821-832
5. Schneerson, R., Barrera, O., Sutton, A., and Robbins, J. B. (1980) J. Exp. Med. 152, 361-376
6. Goldblatt, D. (1998) J. Med. Microbiol. 47, 563-567
7. McCool, T. L., Harding, C. V., Greenspan, N. S., and Schreiber, J. R. (1999) Infect. Immun. 67, 4862-4869
8. Moe, G. R., Tan, S., and Granoff, D. M. (1999) FEMS Immunol. Med. Microbiol. 26, 209-226
9. Westerink, M. A. J., Giardina, P. C., Apicella, M. A., and Kieber-Emmons, T. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 4021-4025
10. Cunto-Amesty, G., Luo, P., Monzavi-Karbassi, B., Lees, A., and Kieber-Emmons, T. (2001) Vaccine 19, 2361-2368
11. Kieber-Emmons, T., Monzavi-Karbassi, B., Wang, B., Luo, P., and Weiner, D. B. (2000) J. Immunol. 165, 623-627
12. Fleuridor, R., Lees, A., and Pirofski, L. (2001) J. Immunol. 166, 1087-1096
13. Kieber-Emmons, T., Luo, P., Qiu, J., Chang, T. Y., O, I., Blaszczyk-Thurin, M., and Steplewski, Z. (1999) Nat. Biotechnol. 17, 660-665
14. Harris, S. L., Craig, L., Mehroke, J. S., Rashed, M., Zwick, M. B., Kenar, K., Toone, E. J., Greenspan, N., Auzanneau, F. I., Marino, A. J., Pinto, B. M., and Scott, J. K. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 2454-2459
15. Pinilla, C., Appel, J. R., Campbell, G. D., Buencamino, J., Benkirane, N., Muller, S., and Greenspan, N. S. (1998) J. Mol. Biol. 283, 1013-1025
16. Hruby, V. J., and Balse, P. M. (2000) Curr. Med. Chem. 7, 945-970
17. Park, B. W., Zhang, H. T., Wu, C., Berezov, A., Zhang, X., Dua, R., Wang, Q., Kao, G., O'Rourke, D. M., Greene, M. I., and Murali, R. (2000) Nat. Biotechnol. 18, 194-198
18. Gupta, D., Dam, T. K., Oscarson, S., and Brewer, C. F. (1997) J. Biol. Chem. 272, 6388-6392
19. Dam, T. K., Roy, R., Das, S. K., Oscarson, S., and Brewer, C. F. (2000) J. Biol. Chem. 275, 14223-14230
20. Dam, T. K., Oscarson, S., Sacchettini, J. C., and Brewer, C. F. (1998) J. Biol. Chem. 273, 32826-32832
21. Balzarini, J., Schols, D., Neyts, J., Van Damme, E., Peumans, W., and De Clercq, E. (1991) Antimicrob. Agents Chemother. 35, 410-416
22. Arendrup, M., Sonnerborg, A., Svennerholm, B., Akerblom, L., Nielsen, C., Clausen, H., Olofsson, S., Nielsen, J. O., and Hansen, J. E. (1993) J. Gen. Virol. 74, 855-865
23. Gattegno, L., Ramdani, A., Jouault, T., Saffar, L., and Gluckman, J. C. (1992) AIDS Res. Hum. Retroviruses 8, 27-37
24. Geijtenbeek, T. B., Kwon, D. S., Torensma, R., van Vliet, S. J., van Duijnhoven, G. C., Middel, J., Cornelissen, I. L., Nottet, H. S., KewalRamani, V. N., Littman, D. R., Figdor, C. G., and van Kooyk, Y. (2000) Cell 100, 587-597
25. Mbemba, E., Carre, V., Atemezem, A., Saffar, L., Gluckman, J. C., and Gattegno, L. (1996) AIDS Res. Hum. Retroviruses 12, 47-53
26. Robinson, W. J., Montefiori, D. C., and Mitchell, W. M. (1987) AIDS Res. Hum. Retroviruses 3, 265-282
27. Saifuddin, M., Hart, M. L., Gewurz, H., Zhang, Y., and Spear, G. T. (2000) J. Gen. Virol. 81, 949-955
28. Geijtenbeek, T. B., Torensma, R., van Vliet, S. J., van Duijnhoven, G. C., Adema, G. J., van Kooyk, Y., and Figdor, C. G. (2000) Cell 100, 575-585
29. Lin, C. L., Sewell, A. K., Gao, G. F., Whelan, K. T., Phillips, R. E., and Austyn, J. M. (2000) J. Exp. Med. 192, 587-594
30. Kaur, K. J., Khurana, S., and Salunke, D. M. (1997) J. Biol. Chem. 272, 5539-5543
31. Jain, D., Kaur, K. J., Goel, M., and Salunke, D. M. (2000) Biochem. Biophys. Res. Commun. 272, 843-849
32. Zhu, X., Borchers, C., Bienstock, R. J., and Tomer, K. B. (2000) Biochemistry 39, 11194-11204
33. Muller, W. E., Schroder, H. C., Reuter, P., Maidhof, A., Uhlenbruck, G., and Winkler, I. (1990) AIDS 4, 159-162
34. Muller, W. E., Bachmann, M., Weiler, B. E., Schroder, H. C., Uhlenbruck, G., Shinoda, T., Shimizu, H., and Ushijima, H. (1991) J. Acquired Immune Defic. Syndr. 4, 694-703
35. Bohm, H. J. (1992) J. Comput. Aided Mol. Des. 6, 593-606
36. Murali, R., and Kieber-Emmons, T. (1997) J. Mol. Recognit. 10, 269-276
37. Kieber-Emmons, T., Lin, C., Foster, M. H., and Kleyman, T. R. (1999) J. Biol. Chem. 274, 9648-9655
38. Lin, C., Kieber-Emmons, T., Villalobos, A. P., Foster, M. H., Wahlgren, C., and Kleyman, T. R. (1994) J. Biol. Chem. 269, 2805-2813
39. Luo, P., Canziani, G., Cunto-Amesty, G., and Kieber-Emmons, T. (2000) J. Biol. Chem. 275, 16146-16154
40. Soule, H. D., Vazguez, J., Long, A., Albert, S., and Brennan, M. (1973) J. Natl. Cancer Inst. 51, 1409-1416
41. Luo, P., Agadjanyan, M., Qiu, J., Westerink, M. A., Steplewski, Z., and Kieber-Emmons, T. (1998) Mol. Immunol. 35, 865-879
42. Bhattacharyya, L., Fant, J., Lonn, H., and Brewer, C. F. (1990) Biochemistry 29, 7523-7530
43. Smith, S. D., Shatsky, M., Cohen, P. S., Warnke, R., Link, M. P., and Glader, B. E. (1984) Cancer Res. 44, 5657-5660
44. Chesebro, B., and Wehrly, K. (1988) J. Virol. 62, 3779-3788
45. Pincus, S. H., Wehrly, K., and Chesebro, B. (1989) J. Immunol. 142, 3070-3075
46. Ratner, L., Haseltine, W., Patarca, R., Livak, K. J., Starcich, B., Josephs, S. F., Doran, E. R., Rafalski, J. A., Whitehorn, E. A., and Baumeister, K. (1985) Nature 313, 277-284
47. Popovic, M., Sarngadharan, M. G., Read, E., and Gallo, R. C. (1984) Science 224, 497-500
48. Popovic, M., Read-Connole, E., and Gallo, R. C. (1984) Lancet 2, 1472-1473
49. Shaw, G. M., Hahn, B. H., Arya, S. K., Groopman, J. E., Gallo, R. C., and Wong-Staal, F. (1984) Science 226, 1165-1171
50. Gallo, R. C., Salahuddin, S. Z., Popovic, M., Shearer, G. M., Kaplan, M., Haynes, B. F., Palker, T. J., Redfield, R., Oleske, J., and Safai, B. (1984) Science 224, 500-503
51. Salter, R. D., Howell, D. N., and Cresswell, P. (1985) Immunogenetics 21, 235-246
52. Johnson, V. A., and Byington, R. E. (1990) in Techniques in HIV Research (Aldovini, A. , and Walker, B., eds) , pp. 71-76, Stockton Press, New York
53. Haertle, T., Carrera, C. J., Wasson, D. B., Sowers, L. C., and Richman, D. D. (1988) J. Biol. Chem. 263, 5870-5875
54. Harada, S., Koyanagi, Y., and Yamamoto, N. (1985) Science 229, 563-566
55. Naismith, J. H., and Field, R. A. (1996) J. Biol. Chem. 271, 972-976
56. Moothoo, D. N., and Naismith, J. H. (1998) Glycobiology 8, 173-181
57. Kneller, D. G., Cohen, F. E., and Langridge, R. (1990) J. Mol. Biol. 214, 171-182
58. Murthy, M. R., Bhuvaneswari, M., Subramanya, H. S., Gopinath, K., and Savithri, H. S. (1997) Biophys. Chem. 68, 33-42
59. Lopalco, L., De Santis, C., Meneveri, R., Longhi, R., Ginelli, E., Grassi, F., Siccardi, A. G., and Beretta, A. (1993) Eur. J. Immunol. 23, 2016-2021
60. Arthur, L. O., Bess, J. W., Jr., Sowder, R. C. D., Benveniste, R. E., Mann, D. L., Chermann, J. C., Henderson, L. E., Chance, M. R., Sagi, I., Wirt, M. D., Frisbie, S. M., Scheuring, E., Chen, E., South, TL, Bailis, A. M., Arthur, L., Rothstein, R., Bowers, M. A., Serabyn, S. A., Johnson, D. G., Bryant, D. K., Fenselau, C., Powell, P. J., Issaq, H. J., Schumack, L. J., and Grimes, M. K. (1992) Science 258, 1935-1938
61. Zou, W., Mackenzie, R., Therien, L., Hirama, T., Yang, Q., Gidney, M. A., and Jennings, H. J. (1999) J. Immunol. 163, 820-825
62. Lo-Man, R., Vichier-Guerre, S., Bay, S., Deriaud, E., Cantacuzene, D., and Leclerc, C. (2001) J. Immunol. 166, 2849-2854
63. Kudryashov, V., Glunz, P. W., Williams, L. J., Hintermann, S., Danishefsky, S. J., and Lloyd, K. O. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 3264-3269
64. O, I., Kieber-Emmons, T., Otvos, L., and Blaszczyk-Thurin, M. (2000) Biochem. Biophys. Res. Commun. 268, 106-111
65. Hansen, J. E., Jansson, B., Gram, G. J., Clausen, H., Nielsen, J. O., and Olofsson, S. (1996) Arch. Virol. 141, 291-300

Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
A. D. Pashov, J. Plaxco, S. V. Kaveri, B. Monzavi-Karbassi, D. Harn, and T. Kieber-Emmons
Multiple Antigenic Mimotopes of HIV Carbohydrate Antigens: Relating Structure and Antigenicity
J. Biol. Chem., October 6, 2006; 281(40): 29675 - 29683.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M.-J. Clement, A. Fortune, A. Phalipon, V. Marcel-Peyre, C. Simenel, A. Imberty, M. Delepierre, and L. A. Mulard
Toward a Better Understanding of the Basis of the Molecular Mimicry of Polysaccharide Antigens by Peptides: THE EXAMPLE OF SHIGELLA FLEXNERI 5A
J. Biol. Chem., January 27, 2006; 281(4): 2317 - 2332.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Pashov, G. Canziani, B. Monzavi-Karbassi, S. V. Kaveri, S. MacLeod, R. Saha, M. Perry, T. C. VanCott, and T. Kieber-Emmons
Antigenic Properties of Peptide Mimotopes of HIV-1-associated Carbohydrate Antigens
J. Biol. Chem., August 12, 2005; 280(32): 28959 - 28965.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
R. W. Sanders, M. Venturi, L. Schiffner, R. Kalyanaraman, H. Katinger, K. O. Lloyd, P. D. Kwong, and J. P. Moore
The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120
J. Virol., June 14, 2002; 76(14): 7293 - 7305.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow An addition or correction has been published
Right arrow All Versions of this Article:
276/32/30490    most recent
M103257200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cunto-Amesty, G.
Right arrow Articles by Kieber-Emmons, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cunto-Amesty, G.
Right arrow Articles by Kieber-Emmons, T.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement